[Clinical features in @entity1892 and translocation XXXX / @entity517 "double hit" @entity706 ].

@entity1 @entity588 @entity706 @entity3726 @entity517 @entity2225 @entity14546 @entity2282 @entity4042 @entity1892 @entity880
@entity1892 ( @entity1892 ) is classified as @entity706 and various entities using the gene expression of proteins are classified into three groups. The aim of this study was to clarify the clinical, biological, immunophenotypic and cytogenetic features of @entity1892 with translocation t (14; 18) and 8q24/ @entity517 . Eleven @entity1892 @entity1 with dual translation were monitored during the 2000-2009 period. The characteristics of these @entity1 included morphological, immunohistochemical and cytogenetic analysis. Study results showed that all @entity1 had aggressive characteristics, presence of B symptoms (64%), general @entity1 condition according to ECOG scale >=  2 (55%), elevated serum @entity880 dehydrogenase activity (73%), clinical stage III and IV (82%), extranodal involvement of the disease (73%), and IPI >=  2 (73%). Partial remission was achieved in 73% of all @entity1 and all @entity1 (73%) died within a short time. @entity1 were treated with @entity3726 and similar protocols (COP, CVP, CNOP), with the addition of MabThera. Immunophenotyping was performed and determined expression of the @entity2225 , CD3, @entity2282 , @entity4042 and @entity14546 markers. The cytogenetic analysis/fluorescence in situ hybridization revealed complex karyotype changes. Thus, we analyzed the presence of @entity588 , @entity4042 and @entity517 genes and found eight @entity1 to have @entity588 and @entity517 translocation genes, while three had translocation of the @entity4042 and @entity517 genes. Despite appropriate therapy, the @entity1 prognosis is poor. The median survival in these @entity1 was 1.85 years. @entity1892 with @entity588 and @entity517 rearrangement of the subgroups of @entity706 is associated with very poor survival. The presence of these two translocations has an aggressive clinical course.
